İ. Çelik

4.8k total citations · 1 hit paper
125 papers, 3.3k citations indexed

About

İ. Çelik is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, İ. Çelik has authored 125 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 24 papers in Molecular Biology. Recurrent topics in İ. Çelik's work include Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (10 papers) and Blood Coagulation and Thrombosis Mechanisms (8 papers). İ. Çelik is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (10 papers) and Blood Coagulation and Thrombosis Mechanisms (8 papers). İ. Çelik collaborates with scholars based in Türkiye, Germany and United States. İ. Çelik's co-authors include Igor Bondarenko, Carsten Bokemeyer, İhsan Ertenli, Sedat Kiraz, Meral Çalgünerı, P. Koralewski, Filippo de Braud, J.T. Hartmann, M. Schlichting and Gunter Schuch and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

İ. Çelik

118 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

2011 612 citations Carsten Bokemeyer, Igor Bondarenko et al. Annals of Oncology profile →

Peers

Countries citing papers authored by İ. Çelik

Since Specialization

Citations

This map shows the geographic impact of İ. Çelik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by İ. Çelik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites İ. Çelik more than expected).

Fields of papers citing papers by İ. Çelik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by İ. Çelik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by İ. Çelik. The network helps show where İ. Çelik may publish in the future.

Co-authorship network of co-authors of İ. Çelik

This figure shows the co-authorship network connecting the top 25 collaborators of İ. Çelik. A scholar is included among the top collaborators of İ. Çelik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with İ. Çelik. İ. Çelik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of oxadiazole- N -phenylacetamide conjugates as VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative assessment, molecular docking, and dynamics studies 2025 ·Future Medicinal Chemistry ·(unknown), Rezk R. Ayyad, İ. Çelik, Helmy Sakr, Alaa Elwan	0
2	Novel triazoloquinazoline derivatives as VEGFR inhibitors: synthesis, cytotoxic evaluation and in silico studies 2025 ·Future Medicinal Chemistry ·(unknown), (unknown), Abdallah E. Abdallah, İ. Çelik, (unknown), (unknown), (unknown), (unknown), Ahmed B. M. Mehany, Mohamed Ayman El‐Zahabi	2
3	Discovery of New Immunomodulatory Anticancer Thalidomide Analogs: Design, Synthesis, Biological Evaluation and In Silico Studies 2024 ·Chemistry & Biodiversity ·Abdallah E. Abdallah, Ibrahim H. Eissa, Ahmed B. M. Mehany, İ. Çelik, Helmy Sakr, (unknown), Khaled El‐Adl, Mohamed Ayman El‐Zahabi	3
4	Association of Health Care Cost with Quality of Life for Various Types of Cancers 2014 ·Value in Health ·Mutlu Hayran, Deniz Yüce, (unknown), Ece Esin, Saadettin Kılıçkap, Mustafa Erman, İ. Çelik	1
5	Clinical Features and Prognostic Factors of Hodgkin’s Lymphoma: A Single Center Experience 2012 ·Balkan Medical Journal ·Saadettin Kılıçkap, İbrahim Barışta, (unknown), İ. Çelik, Uğur Selek, Ferah Yıldız, Ayşe Kars, (unknown), Gülten Tekuzman	11
6	The results of minimally invasive percutaneous plate osteosynthesis MIPPO in distal and diaphyseal tibial fractures 2012 ·Acta Orthopaedica et Traumatologica Turcica ·(unknown), İ. Çelik, (unknown), (unknown), Mahmut Uğurlu	20
7	65 Yaş ve üzeri popülasyonda kanser sıklığının dağılımı: Hacettepe Üniversitesi Hastaneleri kanser kayıt sistemi sonuçları 2011 ·The Turkish Journal of Geriatrics ·Çağatay Arslan, Saadettin Kılıçkap, Didem Şener Dede, Mutlu Hayran, Mustafa Erman, İ. Çelik, M. Tezer Kutluk	0
8	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study breakdown → 2011 ·Annals of Oncology ·Carsten Bokemeyer, Igor Bondarenko, J.T. Hartmann, Filippo de Braud, Gunter Schuch, Angela Zubel, İ. Çelik, M. Schlichting, P. Koralewski	612
9	Lower bone mineral density in geriatric patients with monoclonal gammopathy of undetermined significance 2007 ·Annals of Hematology ·Ömer Dızdar, Mustafa Erman, Mustafa Cankurtaran, Meltem Halil, Zekeriya Ülger, Burcu Balam Yavuz, Servet Arıoğul, Aslı Pinar, Hakan Harputluoğlu, Ayşe Kars, İ. Çelik	7
10	Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists 2005 ·Clinical Pharmacology & Therapeutics ·Melih O. Babaoğlu, (unknown), (unknown), Reinhold Kerb, Hüseyin Abalı, İ. Çelik, Atilla Bozkurt	58
11	Analysis of Menstrual, Reproductive, and Life-style Factors for Breast Cancer Risk in Turkish Women: A Case-Control Study 2004 ·Medical Oncology ·Betül Oran, İ. Çelik, Mustafa Erman, (unknown), Nurullah Zengin, Figen Demirkazık, Sabahat Tezcan	26
12	Antibiotic prophylaxis influences cardiovascular stability in complicated surgery 2004 ·Inflammation Research ·İ. Çelik, B. Stinner, (unknown), Artur Bauhofer, Μ. Rothmund, W. Dietz	1
13	Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease 2003 ·Rheumatology International ·Mehmet Akif Öztürk, İhsan Ertenli, Sedat Kiraz, İbrahim C. Haznedaroğlu, İ. Çelik, Şerafettin Kirazlı, Meral Çalgünerı	9
14	The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis 2003 ·Clinical Rheumatology ·Meral Çalgünerı, Ş Apraş, Zeynep Özbalkan, İhsan Ertenli, Sedat Kiraz, Mehmet Akif Öztürk, İ. Çelik	26
15	Effects of Subchronic Treatment of Some Plant Growth Regulators on Serum Enzyme Levels in Rats 2002 ·TURKISH JOURNAL OF BIOLOGY ·İ. Çelik	24
16	A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5‐fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma 1998 ·Cancer ·Fikri İçlı, İ. Çelik, Nuri Faruk Aykan, (unknown), Ahmet Demirkazık, Ahmet Özet, (unknown), (unknown), Hakan Akbulut, D. Fırat	10
17	Ifosfamide, Mesna and Epirubicin as Second-Line Chemotherapy in Advanced Breast Cancer 1996 ·Journal of Chemotherapy ·Sedat Kiraz, (unknown), (unknown), İbrahim Barışta, (unknown), İ. Çelik, İbrahim Güllü, Ayşe Kars, Gülten Tekuzman, D. Fırat	5
18	Agranulocytosis, Plasmacytosis, and Thrombocytosis Followed by a Leukemoid Reaction Due to Acute Acetaminophen Toxicity 1996 ·Annals of Pharmacotherapy ·(unknown), İbrahim C. Haznedaroğlu, İ. Çelik, Nilgün Sayınalp, Osman Özcebe, Semra Dündar, (unknown)	8
19	Procarbazine, Ccnu, Vincristine Combination in the Treatment of Brain Tumors 1996 ·Tumori Journal ·İbrahim Güllü, İ. Çelik, Gülten Tekuzman, (unknown), Nilüfer Güler, İbrahim Barışta, (unknown), (unknown), Ayşe Kars, (unknown), Emin Kansu, D. Fırat	3
20	The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet's disease. A randomized clinical trial 1996 ·Arthritis & Rheumatism ·Meral Çalgünerı, Sedat Kiraz, İhsan Ertenli, Mustafa Beneklı, (unknown), İ. Çelik	78

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact